Parisa Hosseinzadeh

Parisa Hosseinzadeh

Auto-generated profile, based on publicly available information

Parisa Hosseinzadeh

Department of Bioengineering, Knight Campus, University of Oregon, Eugene, OR, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2017 in Science
Verified
Journal Article
Closed access
PDF file
PHParisa Hosseinzadeh
Parisa Hosseinzadeh
GBGaurav Bhardwaj
Gaurav Bhardwaj
VMVikram Khipple Mulligan
Vikram Khipple Mulligan
MSMatthew D. Shortridge
Matthew D. Shortridge
TCTimothy W. Craven
Timothy W. Craven
DBDavid Baker
David Baker
Macrocycles by design: Macrocyclic peptides have diverse properties, including antibiotic and anticancer activities. This makes them good therapeutic leads, but screening libraries only cover a fraction of the sequence space available to peptides comprising D and L amino acids. Hosseinzadeh et al. achieved near-complete coverage in sampling the sequence space for 7- to 10-residue cyclic peptides and identified more than 200 designs predicted to fold into stable structures. Of 12 structures determined, nine were close to the computational models. They also sampled and designed 11- to 14-residue macrocycles, but without complete coverage. The designed macrocycles provide a path forward for engineering new therapeutics. Science , this issue p. 1461

14 September 2018 in Science
Verified
Journal Article
Open access
PDF file
EMEvan N. Mirts
Evan N. Mirts
IPIgor D. Petrik
Igor D. Petrik
PHParisa Hosseinzadeh
Parisa Hosseinzadeh
MNMark J. Nilges
Mark J. Nilges
YLYi Lu
Yi Lu
Metals brought together do more: Enzymatic reduction of oxyanions such as sulfite (SO 3 2− ) requires the delivery of multiple electrons and protons, a feat accomplished by cofactors tailored for catalysis and electron transport. Replicating this strategy in protein scaffolds may expand the range of enzymes that can be designed de novo. Mirts et al. selected a scaffold protein containing a natural heme cofactor and then engineered a cavity suitable for binding a second cofactor—an iron-sulfur cluster (see the Perspective by Lancaster). The resulting designed enzyme was optimized through rational mutation into a catalyst with spectral characteristics and activity similar to that of natural sulfite reductases. Science , this issue p. 1098 ; see also p. 1071

7 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
PHParisa Hosseinzadeh
Parisa Hosseinzadeh
PWParis R. Watson
Paris R. Watson
TCTimothy W. Craven
Timothy W. Craven
XLXinting Li
Xinting Li
SRStephen Rettie
Stephen Rettie
DBDavid Baker
David Baker
Despite recent success in computational design of structured cyclic peptides, de novo design of cyclic peptides that bind to any protein functional site remains difficult. To address this challenge, we develop a computational “anchor extension” methodology for targeting protein interfaces by extending a peptide chain around a non-canonical amino acid residue anchor. To test our approach using a well characterized model system, we design cyclic peptides that inhibit histone deacetylases 2 and 6 (HDAC2 and HDAC6) with enhanced potency compared to the original anchor (IC 50 values of 9.1 and 4.4 nM for the best binders compared to 5.4 and 0.6 µM for the anchor, respectively). The HDAC6 inhibitor is among the most potent reported so far. These results highlight the potential for de novo design of high-affinity protein-peptide interfaces, as well as the challenges that remain.

15 March 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
VMVikram Khipple Mulligan
Vikram Khipple Mulligan
SWSean Workman
Sean Workman
TSTianjun Sun
Tianjun Sun
SRStephen Rettie
Stephen Rettie
XLXinting Li
Xinting Li
DBDavid Baker
David Baker
The rise of antibiotic resistance calls for new therapeutics targeting resistance factors such as the New Delhi metallo-β-lactamase 1 (NDM-1), a bacterial enzyme that degrades β-lactam antibiotics. We present structure-guided computational methods for designing peptide macrocycles built from mixtures of l- and d-amino acids that are able to bind to and inhibit targets of therapeutic interest. Our methods explicitly consider the propensity of a peptide to favor a binding-competent conformation, which we found to predict rank order of experimentally observed IC50 values across seven designed NDM-1- inhibiting peptides. We were able to determine X-ray crystal structures of three of the designed inhibitors in complex with NDM-1, and in all three the conformation of the peptide is very close to the computationally designed model. In two of the three structures, the binding mode with NDM-1 is also very similar to the design model, while in the third, we observed an alternative binding mode likely arising from internal symmetry in the shape of the design combined with flexibility of the target. Although challenges remain in robustly predicting target backbone changes, binding mode, and the effects of mutations on binding affinity, our methods for designing ordered, binding-competent macrocycles should have broad applicability to a wide range of therapeutic targets. Significance Peptide macrocycles are a promising class of drugs, but their weakness is conformational flexibility: target affinity can be limited by an unfavorable transition from a disordered unbound state to an ordered bound state. We introduce general computational methods for stabilizing peptide macrocycles in binding-competent conformations as part of the process of designing for binding to a target protein. As a proof of principle, we apply our methods to create inhibitors of the New Delhi metallo-β-lactamase 1, an antibiotic resistance factor. Predictions of peptide rigidity correlate with experimental success, allowing designs to be prioritized for synthesis and testing. These methods should contribute to the design of peptide macrocycle inhibitors of diverse targets of therapeutic interest.

6 December 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
EMEdin Muratspahić
Edin Muratspahić
KDKristine Deibler
Kristine Deibler
JHJianming Han
Jianming Han
NTNataša Tomašević
Nataša Tomašević
KJKirtikumar B. Jadhav
Kirtikumar B. Jadhav
CGChristian Gruber
Christian Gruber
Despite the increasing number of GPCR structures and recent advances in peptide design, the development of efficient technologies allowing rational design of high-affinity peptide ligands for single GPCRs remains an unmet challenge. Here, we develop a computational approach for designing conjugates of lariat-shaped macrocyclized peptides and a small molecule opioid ligand. We demonstrate its feasibility by discovering chemical scaffolds for the kappa-opioid receptor (KOR) with desired pharmacological activities. The designed De Novo Cyclic Peptide (DNCP)-β-naloxamine (NalA) exhibit in vitro potent mixed KOR agonism/mu-opioid receptor (MOR) antagonism, nanomolar binding affinity, selectivity, and efficacy bias at KOR. Proof-of-concept in vivo efficacy studies demonstrate that DNCP-β-NalA(1) induces a potent KOR-mediated antinociception in male mice. The high-resolution cryo-EM structure (2.6 Å) of the DNCP-β-NalA–KOR–Gi1 complex and molecular dynamics simulations are harnessed to validate the computational design model. This reveals a network of residues in ECL2/3 and TM6/7 controlling the intrinsic efficacy of KOR. In general, our computational de novo platform overcomes extensive lead optimization encountered in ultra-large library docking and virtual small molecule screening campaigns and offers innovation for GPCR ligand discovery. This may drive the development of next-generation therapeutics for medical applications such as pain conditions.

16 April 2022 in BioDesign Research
Verified
Journal Article
Open access
PDF file
SGSuchetana Gupta
Suchetana Gupta
NANoora Azadvari
Noora Azadvari
PHParisa Hosseinzadeh
Parisa Hosseinzadeh
Recent years have witnessed a rise in methods for accurate prediction of structure and design of novel functional proteins. Design of functional protein fragments and peptides occupy a small, albeit unique, space within the general field of protein design. While the smaller size of these peptides allows for more exhaustive computational methods, flexibility in their structure and sparsity of data compared to proteins, as well as presence of noncanonical building blocks, add additional challenges to their design. This review summarizes the current advances in the design of protein fragments and peptides for binding to targets and discusses the challenges in the field, with an eye toward future directions.